US drug giant Eli Lilly announced last month that Mounjaro, for treating obesity and type 2 diabetes, had been approved by ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Currently, two innovators are dominating the $50 billion market : Novo Nordisk’s Ozempic or Wegovy (Semaglutide) and Eli ...

Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the ...

Susan McGowan, 58, from Lanarkshire, died from multiple organ failure, septic shock and pancreatitis after taking two ...

Nvidia topping Apple as the most valuable company in the world and joining the Dow Jones Industrial Average. Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 ...

Susan McGowan took two doses of tirzepatide, sold under the brand name Mounjaro, before she died on 4 September ...

FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also used for weight loss, told CBS News: "Lilly has taken steps to help inform people about the ...

Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.

But what makes Altimmune's drug different from existing drugs, and what kind of market opportunity does it have? Altimmune's ...

A SCOTS nurse is thought to be the first person to die in the UK after taking a weight loss injection recently approved by the NHS. Susan McGowan, 58, passed away on September 4 after taking two ...